HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Brian Higgins Selected Research

RG7388

1/2022The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
12/2021Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
1/2021Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
1/2020A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
11/2017Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma.
7/2014Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Brian Higgins Research Topics

Disease

33Neoplasms (Cancer)
12/2021 - 05/2002
5Melanoma (Melanoma, Malignant)
10/2017 - 07/2010
5Breast Neoplasms (Breast Cancer)
04/2016 - 07/2007
4Colorectal Neoplasms (Colorectal Cancer)
02/2012 - 04/2007
3Prostatic Neoplasms (Prostate Cancer)
05/2011 - 05/2002
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021 - 10/2020
2Polyploidy
10/2017 - 08/2010
2Febrile Neutropenia
06/2015 - 09/2009
1Polycythemia Vera
01/2022
1Glioblastoma (Glioblastoma Multiforme)
11/2017
1Neoplasm Micrometastasis
04/2016
1Arthralgia (Joint Pain)
06/2015
1Pain (Aches)
06/2015
1Myalgia
06/2015
1Osteosarcoma (Osteogenic Sarcoma)
07/2014
1Colonic Neoplasms (Colon Cancer)
08/2011
1Endophthalmitis (Ophthalmia)
08/2011
1Adenocarcinoma
07/2007
1Corneal Neovascularization
04/2006
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2004
1Retinoblastoma (Glioblastoma, Retinal)
05/2002

Drug/Important Bio-Agent (IBA)

6RG7388IBA
01/2022 - 07/2014
6Phosphotransferases (Kinase)IBA
10/2017 - 11/2006
4Pharmaceutical PreparationsIBA
10/2017 - 05/2002
4AndrogensIBA
04/2013 - 05/2002
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2012 - 03/2009
4Capecitabine (Xeloda)FDA Link
01/2010 - 07/2007
3VemurafenibIBA
02/2012 - 07/2010
3Bevacizumab (Avastin)FDA Link
01/2009 - 07/2007
2RO6839921IBA
10/2020 - 01/2020
2ErbB Receptors (EGF Receptor)IBA
04/2016 - 06/2004
2Estrogen ReceptorsIBA
04/2016 - 07/2007
2Docetaxel (Taxotere)FDA Link
06/2015 - 09/2009
2Codon (Codons)IBA
02/2012 - 07/2010
2Proto-Oncogene Proteins B-rafIBA
01/2012 - 09/2010
2nutlin 3IBA
05/2011 - 02/2006
2Androgen Receptors (Androgen Receptor)IBA
05/2011 - 05/2002
2Proteins (Proteins, Gene)FDA Link
07/2010 - 05/2002
2Mitogen-Activated Protein KinasesIBA
01/2010 - 03/2009
2Irinotecan (Camptosar)FDA LinkGeneric
01/2009 - 04/2007
2Tyrosine Kinase InhibitorsIBA
04/2007 - 06/2004
2Erlotinib Hydrochloride (CP 358,774)FDA Link
04/2007 - 06/2004
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2006 - 10/2002
1PowdersIBA
12/2021
1Cytarabine (Cytosar-U)FDA LinkGeneric
01/2021
1Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
11/2020
1ProdrugsIBA
01/2020
1Glucose (Dextrose)FDA LinkGeneric
11/2017
1DNA (Deoxyribonucleic Acid)IBA
10/2017
1pegfilgrastim (Neulasta)FDA Link
06/2015
1Filgrastim (Neupogen)FDA Link
06/2015
1RO8994IBA
08/2014
1RG7112IBA
04/2013
1Biomarkers (Surrogate Marker)IBA
04/2013
1Angiogenesis InhibitorsIBA
02/2013
1Intravenous Immunoglobulins (IVIG)FDA Link
08/2011
1AntitoxinsIBA
08/2011
1Bacterial ToxinsIBA
08/2011
1Immunoglobulin G (IgG)IBA
08/2011
1Immunoglobulins (Immunoglobulin)IBA
08/2011
1Interleukin-6 (Interleukin 6)IBA
06/2011
1Interleukin-8 (Interleukin 8)IBA
06/2011
12,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA
06/2011
1Amyloid Precursor Protein Secretases (beta-Secretase)IBA
06/2011
1Hormones (Hormone)IBA
05/2011
1Protein Kinases (Protein Kinase)IBA
09/2010
1NocodazoleIBA
08/2010
1TubulinIBA
08/2010
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
07/2010
1MitogensIBA
07/2010
12- (4- (4- (2,3- dihydroxy- propoxy)phenyl)- 2,5- dioxo- imidazolidin- 1- yl)- N- (2- fluoro- 4- iodo- phenyl)- 3- phenylbutyramideIBA
01/2010
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
09/2009
1(2S,3S)- 2- ((R)- 4- (4- (2- hydroxyethoxy)phenyl)- 2,5- dioxo- imidazolidin- 1- yl)- 3- phenyl- N- (4- propionylthiazol- 2- yl)butyramideIBA
03/2009
1MAP Kinase Kinase 1IBA
03/2009
1Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2009
1Taxoids (Taxanes)IBA
07/2007
1AnthracyclinesIBA
07/2007
1Retinoblastoma ProteinIBA
11/2006
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
08/2006
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
08/2006
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
08/2006
1RO0281501IBA
08/2006
1Gadolinium DTPA (Magnevist)FDA Link
08/2006
1Antineoplastic Agents (Antineoplastics)IBA
08/2006
1Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
08/2006
1Biological ProductsIBA
04/2006
1Cisplatin (Platino)FDA LinkGeneric
06/2004
1GemcitabineFDA Link
06/2004
1Cytostatic AgentsIBA
10/2002
1Paclitaxel (Taxol)FDA LinkGeneric
10/2002
1LigandsIBA
08/2002
1tanespimycin (17AAG)IBA
05/2002
1Androgen Antagonists (Antiandrogens)IBA
05/2002

Therapy/Procedure

13Therapeutics
01/2021 - 02/2006
4Drug Therapy (Chemotherapy)
04/2016 - 06/2004
2Castration
05/2011 - 05/2002
1Adjuvant Chemotherapy
06/2015
1Oral Administration
04/2013